Research

Hormonal

GLP-1 and dual GLP-1/GIP receptor agonists cause predictable, dose-dependent gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) that are generally mild to moderate and transient, though they significantly impact treatment adherence.

Expect digestive side effects like nausea or constipation when starting GLP-1 medications. These are common, usually mild, and tend to improve as your body adjusts. To minimize them, start with the lowest dose and increase slowly as directed by your doctor. Staying hydrated and eating smaller meals can help manage symptoms.

GoodSupportsHIGH confidence
Nausea, vomiting, diarrhea, and constipation were the most frequently reported GI adverse events, generally dose-dependent and transient... GLP-1–based therapies are associated with predictable GI adverse effects, most of which are mild to moderate and manageable.
Nimet Yılmaz et al. · Diabetes Metabolic Syndrome and Obesity · 2026

Why this rating

Based on a comprehensive narrative review of RCTs, meta-analyses, and real-world data, though heterogeneity exists.

Source

Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations

Nimet Yılmaz et al. · Diabetes Metabolic Syndrome and Obesity · 2026

DOI 10.2147/dmso.s584175

narrative_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →